Recursion Pharmaceuticals
RXRX
RXRX
84 hedge funds and large institutions have $1.26B invested in Recursion Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 11 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
6.63% more ownership
Funds ownership: 27.91% → 34.53% (+6.6%)
26% less capital invested
Capital invested by funds: $1.71B → $1.26B (-$451M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Holders
84
Holding in Top 10
4
Calls
$1.48M
Puts
$425K
Top Buyers
| 1 | +$81.5M | |
| 2 | +$29.2M | |
| 3 | +$9.17M | |
| 4 |
YRHAM
Yong Rong (HK) Asset Management
Sheung Wan,
Hong Kong
|
+$8.68M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$7.81M |
Top Sellers
| 1 | -$5.79M | |
| 2 | -$1.84M | |
| 3 | -$1.72M | |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$730K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$548K |